aTyr Pharma Announces Phase 3 Study of Efzofitimod (ATYR1923) in Pulmonary Sarcoidosis
May 16, 2022 08:00 ET
|
aTyr Pharma, Inc.
Global pivotal EFZO-FIT™ study expected to begin in the third quarter of 2022 Primary endpoint will evaluate steroid sparing effect of efzofitimod compared to placebo SAN DIEGO, May 16, 2022 ...